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The polymer polydimethylsiloxane (PDMS) is widely used to build microﬂuidic devices compatible with
cell culture. Whilst convenient in manufacture, PDMS has the disadvantage that it can absorb small
molecules such as drugs. In microﬂuidic devices like “Organs-on-Chip”, designed to examine cell
behavior and test the effects of drugs, this might impact drug bioavailability. Here we developed an assay
to compare the absorption of a test set of four cardiac drugs by PDMS based on measuring the residual
non-absorbed compound by High Pressure Liquid Chromatography (HPLC). We showed that absorption
was variable and time dependent and not determined exclusively by hydrophobicity as claimed previ-
ously. We demonstrated that two commercially available lipophilic coatings and the presence of cells
affected absorption. The use of lipophilic coatings may be useful in preventing small molecule absorption
by PDMS.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Differences in physiology can compromise the ability of animal
models to predict drug responses in humans accurately. As a result,
inappropriatedrugsmayenter clinical trials oruseful drugsdiscarded
unnecessarily early in development. One of the most common
adverse drug effects is still cardiotoxicity despite use of ion channel
(“hERG”) assays to predict arrhythmic risk, illustrating the urgent
need for improvement in human cardiac models [1]. In this context,
the Food and Drug Association (FDA) recently initiated the Compre-
hensive In Vitro Proarrhythmia Assay (CIPA) (cipaproject.org), tobryology, Leiden University
he Netherlands.
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r Inc. This is an open access articleassess cardiac drug safety using cardiomyocytes from human
pluripotent stemcells. Among themodelsbeingexaminedare several
incorporating cardiomyocytes into polymer-based devices or micro-
tissues [2e4] rather than conventional tissue culture substrates like
glass and plastic, which are orders of magnitude harder and less
elastic than cellswould normally encounter in tissue. Resulting stress
can inﬂuence cell behavior profoundly and thus drug responses
[5e7]. Soft polymer substrates like polydimethylsiloxane (PDMS) are
preferred by bioengineers because they can be used to fabricate
microﬂuidic channels, ﬂexible membranes and provide topological
cues to recapitulate blood vessels, mechanical tissue strain and
induce cell orientation [8e10]. Furthermore, sensors that measure
electrical activity, metabolic behavior, ion transport and force of
contraction can be integrated as readouts [2,11]. PDMS-based Organ-
on-Chip devices can also be used for live cell imaging and are
compatible with immunoassays, disease phenotyping and drug
testing [12,13]. Soft polymer-based microﬂuidic assays have long
been used for multiple biological purposes [14] but PDMS most
commonly because of its biocompatibility, transparency, ease of
microfabrication, molding properties and tunable substrateunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mimicking tissues that undergo cyclic stretch and strain in the body,
suchas the lungsorheart [2,8,11].Oneof its drawbacks,however, is its
absorption of compounds added to culture medium in bioassays,
most particularly, hydrophobic small molecules like many drugs
[16e18]. This reduces the available drug dose, shifts the dose
response curve and thus limits the predictive value of assays.
There have been few direct comparisons of absorption of
different compounds by PDMS with other (more inert) substrates
and how cell culture affects absorption has not been investigated.
Toepke et al. examined the absorption of hydrophobic small mol-
ecules qualitatively with a ﬂuorescence assay but this was not
quantitative [17]. Wang et al. did assess ﬁnal compound concen-
tration quantitatively over time and determined a threshold that
distinguished compounds with negligible absorption from those
where it was signiﬁcant, based on the log P value [18], a measure of
hydrophobicity. It was claimed that all compounds with a log P
value greater than 2.67 would show high absorption by PDMS
substrates. In addition, they tested whether glass and titanium
dioxide coatings reduced compound binding. These coatings have
been reported to be biocompatible [16], but the presence of cells on
compound absorption or coating degradation has not been inves-
tigated. Parylene coating has also been reported [19], but it com-
promises important properties of PDMS, such as its elasticity and
gas permeability.
Here, we determined small molecule absorption by PDMS-
coated culture wells versus standard culture plastic for four drugs
that affect the heart, our primary research area [20,21] for which
there is interest in knowing their toxic threshold: verapamil,
bepridil, Bay K 8644 and nifedipine. Toxic thresholds can only be
determined accurately if the compound availability to cells is
known. We therefore investigated whether cell density affected
absorption and tested the ability of two commercial coatings
(available on request) to reduce absorption, without affecting
biocompatibility or cell plating [22]. Finally, we combined a com-
mercial coating with cell culture to investigate the combined effect
on the free drug concentration over time of incubation.
2. Experimental
2.1. Preparation of plates
Standard tissue culture grade polystyrene (TCPS) 96-well
CELLSTAR® multiplates (Greiner Bio-One, Germany) were used.
For PDMS absorption experiments, bottoms of wells were coated
with 20 mL PDMS Sylgard 184 (Dow Corning, Auburn, MI), 1:10 wt
ratio curing agent to elastomer. LipoCoat Cellbinder (LipoCoat,
Enschede, The Netherlands) was used to coat oxygen plasma
treated PDMS-coated 96-wells plates (PDMS Sylgard 184, Dow
Corning, Auburn, MI).
2.2. Experimental procedure and sample retrieval
Verapamil, nifedipine (Sigma Aldrich, Saint Louis, MO), bepridil
and Bay K 8644 (Tocris, United Kingdom) were diluted in dime-
thylsulfoxide (DMSO; Sigma Aldrich) to obtain 1 mM stock. This
was diluted 1:1000 in Dulbecco's Phosphate Buffered Saline
without calcium andmagnesium (DPBS) or in Tyrode's buffer when
cells were present, to aworking concentration of 1 mM. All solutions
were prepared in disposable glass vials. 250 mL of the working so-
lution was pipetted into the TCPS or PDMS wells and incubated for
0.5, 1, 2 or 3 h before being gently mixed with a pipette and
transferred to a glass vial which was sealed immediately. In addi-
tion, 250 mL of the working solution was pipetted into a glass vial
for every sample group at the start of the experiment to providebaseline values (concentration at time zero). Time points were
chosen to allow <10% change in absorption at the ﬁnal time point
for all compounds. Experiments were in duplicate. Cell culture
experiments were at 37 C; other experiments were at room
temperature.
3. HPLC
Drug concentrations were determined by HPLC using a solvent
delivery system from Gilson (Middleton, WI) equipped with a Gil-
son auto injector. A VI/VIZ detector (Applied Biosystems 759A;
Thermo Fisher Scientiﬁc, Waltham, MA) was used, monitoring the
UV absorption maximum of the compounds under investigation. A
Discovery® column (125  4.6 mm; Supelco, Bellefonte, PA) was
applied, with a stationary phase of C18, 5 mM particles. As mobile
phase, MeCN was used at 40e65% (depending on the compound),
5 mM SDS and 0.1% TFA. Flow speed was 0.8 ml/min and the in-
jection volume 100 ml. Recording and processing of data was per-
formed using ADchom software (Leiden University, the
Netherlands). In every experiment a calibration curve was included
to validate the system and the linearity of the compound UV ab-
sorption response. Measurements were performed in duplicate or
triplicate, as indicated. Averages from individual experiments are
shown in the graphs. Since replicates showed little spread, n ¼ 2
was standard for non-biological assays.
3.1. Cell culture
Human Embryonic Kidney 293T (HEK293T) cells were main-
tained in Dulbecco's Modiﬁed Eagle Medium (DMEM) supple-
mented with 2 mM L-glutamine, 10 mM non-essential amino acids
(NEAA), 25 U/ml penicillin, 25 mg/ml streptomycin (Thermo Fisher
Scientiﬁc), and 10% fetal calf serum (FCS) (Sigma Aldrich). Culture
mediumwas refreshed every 3e4 days. For experiments, cells were
dissociated from standard 6 well tissue culture plates (Greiner Bio-
One, Germany) with 0.1% trypsin and plated in 96-well plates at
three densities: 9  103, 37  103 and 117  103 cells per well
(0.3 cm2) corresponding to low, medium and high surface coverage,
respectively.
3.2. Cell staining
Cells were brieﬂy washed with PBS before ﬁxation with 2%
neutral paraformaldehyde for 30 min at room temperature. Next,
cells were permeabilized for 8 min with 0.1% Triton X-100 (Sigma
Aldrich) in PBS then preincubated with 4% FCS in PBS for 1 h to
block non-speciﬁc binding. Cells were incubated with PBS plus
Alexa Fluor 488 Phalloidin (1:40; Invitrogen) and 4% FCS for 30min.
Finally, cells were incubated with PBS plus DAPI Nucleic Acid Stain
(1:1000; Invitrogen) before glass coverslips were mounted on top
of the PDMS with ProlongGold (Thermo Fisher Scientiﬁc). Between
every step, cells were washed with PBS and prior to Phalloidinwith
PBS plus 0.05% Tween 20 (Merck, Germany).
4. Results
HPLC was used to measure the free drug concentrations in PBS.
Four compounds that affect cardiac behaviour and of interest to
validate in cardiotoxicity models in vitrowere incubated for 0.5, 1, 2
and 3 h on TCPS wells with PDMS as the base and compared to the
absorption by standard TCPS wells after 3 h (Fig. 1). Absorption by
TCPS, measured as loss of compound from solution, was negligible
or low but detectable for Bay K 8644, verapamil and nifedipine and
somewhat higher for bepridil. PDMS however absorbed com-
pounds much more variably: verapamil and nifedipine were
Fig. 1. Free drug concentration lifetime for incubation on TCPS and PDMS. Free drug concentration after 0.5, 1, 2 and 3 h incubation on PDMS and 3 h on TCPS of A) Bay K 8644, B)
bepridil, C) nifedipine and D) verapamil. Averages from two independent experiments are shown.
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there was no difference between TCPS and PDMS. Bepridil was
strikingly reduced more than 80% by PDMS after 3 h. To exclude
compound degradation or absorption of the compounds by glass
storage vials, Bay K 8644 and bepridil solutions were kept in glass
containers for 3 h and compared with the starting concentrations
(Fig. S1). No differences were observed. All compounds reached
steady state (<10% concentration change) both on PDMS and TCPS.
To investigate whether compound hydrophobicity, molecular
weight or topological polar surface area was correlated with the
absorption by PDMS, the ﬁnal free drug concentration was plotted
as described previously [18]. The log P values of the compounds
used here were 4.03 (Bay K 8644 [23]), 8.0 (bepridil [24]) and 3.79
(verapamil [25]) and ±3 (nifedipine; provided by the manufac-
turer), but there was no correlation between these values and our
measures of absorption (Fig. 2A). Similarly, no correlation was
found between the measures of absorption and the molecular
weight (Fig. 2B). The correlation between topological polar surface
area and compound absorption by PDMS was linear (R square:
7.61).We also examined the effect of several mixtures of PDMSwith
variable elasticity on absorption [26] but all showed similar high
reduction in free bepridil concentration after 3 h (data not shown)
so we did not pursue this further.
Next, we coated the PDMS surface with Cellbinder, a lipid-based
coating with cell binding properties [22]. To facilitate cell attach-
ment on otherwise zwitterionic, non-fouling and cell repellent
surfaces, positive surface charge had been introduced in the Cell-
binder coating to promote cell adhesion. Two Cellbinder coatings
were compared: Cellbinder and Cellbinderþ, which has greater
stability. After 3 h incubation, bepridil retained higher free drug
concentration, indicating less absorption, on both coatings
compared to uncoated PDMS (Fig. 2D and E). No difference was
found between the two.
Apart from direct substrate effects, culture of cells could also
inﬂuence free compound availability since cells may either absorbcompounds or block absorption sites on the substrate. We therefore
investigated whether HEK293T (kidney cell) culture density on
PDMS substrates affected loss of compounds from solution. Again,
low and high binders (Bay K 8644 and bepridil, respectively) were
incubated at 37 C (Fig. 2F and G). Bay K 8644 was reduced as cell
density increased from 9  103 to 37  103 and 117  103 cells,
respectively, after 0.5 h and 3 h of incubation. A similar effect was
seen for bepridil after 0.5 h although at 3 h, no differences in free
concentration were evident between the three cell densities, all
being equally low.
HEK293T cells were also cultured on TCPS, PDMS, and PDMS
with Cellbinder coating to investigate both biocompatibility and
cell binding properties (Fig. 3). Cell spreading on PDMS was less
than on TCPS and cells remained rounded with reduced visible
cytoskeleton and nuclei closer together. When cultured on PDMS
coated with Cellbinder, more focal adhesion points of the cyto-
skeleton were seen, indicating improved attachment and less
stress.
Finally, different densities of HEK293T cells were cultured on
Cellbinder and Cellbinder þ -coated PDMS substrates and subse-
quently incubated with Bay K 8644 and bepridil to investigate the
effect on free drug concentration (Fig. 4). For Bay K 8644, both
coatings showed increased absorption at the highest cell density
after 0.5 and 3 h, as also shown for uncoated PDMS plus HEK293T
cell culture. For bepridil, there was a difference between the low
and high cell density on the Cellbinder coating after 0.5 h, but this
was not sustained at 3 h.
By analyzing the values found for free drug concentrations of
Bay K 8644 and bepridil incubation after 3 h on different substrates
with and without HEK293T cell culture (medium density) we
compared the effect of the substrate conditions on the ﬁnal free
drug concentrations. Fig. 4C shows a decrease in Bay K 8644 con-
centration on PDMS with HEK293T culture, while there was no
difference between PDMS, coated PDMS and coated PDMS with
HEK293T culture. However, the loss of bepridil concentration on
Fig. 2. Properties and/or conditions that inﬂuence free drug concentration lifetime on PDMS. A) Plot of the ﬁnal free drug concentration of Bay K 8644, bepridil, nifedipine and
verapamil after 3 h of incubation on PDMS set out against their hydrophobicity (log P). B) Plot of the ﬁnal free drug concentration of Bay K 8644, bepridil, nifedipine and verapamil
after 3 h incubation on PDMS versus their molecular weight. C) Plot of the ﬁnal free drug concentration of Bay K 8644, bepridil, nifedipine and verapamil after 3 h of incubation on
PDMS versus their topological polar surface area and ﬁtted with a linear best ﬁt (dotted line, R square: 7.61). D) and E) plots of the free drug concentration of Bay K 8644 and
bepridil, respectively, after 0, 0.5 and 3 h of incubation on PDMS coated with Cellbinderþ, Cellbinder and without coating. F) and G) plots of the free drug concentration of Bay K
8644 and bepridil, respectively, after 0, 0.5 and 3 h of incubation at low, medium and high plating cell densities on PDMS substrates. Averages from two independent experiments
are shown.
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strates; there was no effect of the absence or presence of cell
cultures.
5. Discussion
Cell culture devices made from PDMS are widely used in mul-
tiple formats but may bind molecules selectively from the medium,Fig. 3. Commercial coating for PDMS to reduce drug binding and cell plating. Representa
and nuclei (blue), on A) TCPS, B) PDMS and C) Cellbinder coated PDMS. White bars indicate 2
ﬁgure legend, the reader is referred to the web version of this article.)reducing their effective availability to cells. The study here showed
that several cardio-active compounds differed in their absorption
by TCPS-wells with PDMS base versus standard TCPS-wells. The
presence of PDMS signiﬁcantly affected the free concentration of
compounds. Bepridil was most highly absorbed by TCPS with PDMS
base after 3 h, followed by verapamil. Nifedipine and Bay K 8644
retained the highest free drug levels after the longest incubation
time. No relationship was found between the reduction aftertive images of HEK293T, brightﬁeld and ﬂuorescent staining of the cytoskeleton (green)
5 mm, black bars indicate 350 mm. (For interpretation of the references to colour in this
Fig. 4. Effect of cell density on coated PDMS. A), B), D) and E) show plots of the free drug concentration of Bay K 8644 and bepridil after 0, 0.5 and 3 h of incubation at low, medium
and high cell plating densities on PDMS coated with Cellbinderþ (Cþ) and Cellbinder (C). C) Summary of the effect of the ﬁnal free drug concentration of Bay K 8644 and bepridil
after 3 h of incubation on PDMS, Cellbinder coated PDMS, PDMS plus HEK293T cell culture and Cellbinder coated PDMS plus HEK293T cell culture. Averages from two independent
experiments are shown.
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example, Bay K 8644 was reduced equally on both substrates whilst
verapamil was reduced >50% on PDMS but not on TCPS. After 3 h of
incubation, all compounds reached steady state (<10% concentra-
tion change) on PDMS, indicating saturation of the substrate. We
estimated that the total reduction of bepridil concentration would
be ±85% with a surface area of 0.3 cm2 and volume of 250 mL,
indicating a free concentration of 150 nM instead of 1 mM after 3 h
incubation. Typically, in a microﬂuidic chamber, the volume-to-
surface ratio would be lower. For example, a PDMS microﬂuidic
channel might normally have dimensions 50  5 mm length x
width and 200 mm height, equivalent to 5.20 cm2 surface and 50 mL
volume. Since the volume-to-surface ratio increases more than 86
times, the reduction in free compound concentration could be ex-
pected to increase similarly, highlighting the importance of this
issue.
According to the log P threshold of 2.67 based on ﬁve com-
pounds predicted by Wang et al. all compounds we examined
should have shown high absorption but this was not the case. More
importantly, we were unable to ﬁnd a clear correlation between
absorption and log P, suggesting that hydrophobicity is not the
(single) parameter determining compound absorption by PDMS as
proposed by Wang et al. Molecular weight of the compounds was
also not correlated with the absorption by PDMS, nor did a com-
bination of the log P value and molecular weight. We conclude that
hydrophobicity andmolecular weight are not the (only) parameters
determining small molecule drug binding as previously suggested.
Topological polar surface area indicated a linear relationship with
absorption, but this should be conﬁrmed by measurements with
more compounds.
Ways to reduce compound absorption by PDMS speciﬁcally are
of great interest. Two variants of a commercially available coating
for PDMS were tested. These differed in chemical stability accord-
ing to the manufacturer: Cellbinderþ is stable when exposed to air,
whilst the regular variant of Cellbinder must be kept hydrated. The
coatings are lipid-based and designed to mimic natural cellmembrane interface. These types of materials are resistant to sur-
face accumulation of proteins and can also act as barriers, pre-
venting passage of molecules through the layer [22]. Both coatings
had similar blocking properties with respect to the absorption by
PDMS. They reduced the high absorption of bepridil by PDMS of
>80% after 3 h to approximately 50%. Also, absorption of Bay K 8644
was reduced compared to uncoated surfaces, although only slightly.
HEK293T cells were used as a model to investigate the
biocompatibility of the coating and also whether cells confounded
absorption. HEK293Tcells express endogenous calcium and sodium
channels [27,28], although these calcium channels are insensitive
to the calcium channel speciﬁc Bay K 8644 [28]. The binding of
bepridil was expected to be higher since it is non-selective com-
pound and known to block both calcium and sodium channels [29].
However, after incubation of 3 h on PDMS plated with HEK293T
cells, the free concentration of Bay K 8644 was highly reduced
compared to incubation on PDMS only. The effect of compound
absorption by cells is more pronounced than their potential to block
compound absorption by the substrate, showing greater reduced
free compound concentration at the high cell density compared to
the low cell density. In contrast, the absorption of bepridil was not
affected by the presence of cells. Since the absorption of bepridil by
PDMS is very high, any reduction caused by the introduction of the
HEK293T cells might be masked by the dominant substrate effect.
For PDMS coatings to be of practical use in cell culture assays
they should be biocompatible and support cell attachment. Un-
coated PDMS is biocompatible, but cells only attach following
surface treatments such as the exposure to an oxygen plasma or
ultra violet light [30,31]. However, these treatments would destroy
organic molecules like Cellbinder. An ideal coating would facilitate
similar or better cell adherence than regular PDMS, without surface
pre-treatment. Although most focal adhesion points were evident
in HEK293T cells cultured on TCPS and the cytoskeleton showed
greater cell spreading, Cellbinder-coated PDMS also supported
adequate cell adherence, demonstrating its potential utility
through both biocompatibility and cell adherence although
B.J. van Meer et al. / Biochemical and Biophysical Research Communications 482 (2017) 323e328328adherence was lower than on TCPS.
Cellbinder-coated PDMS to which HEK293T cells were attached
showed reduced compound absorption, both for Bay K 8644 and
bepridil. The reduction in Bay K 8644 reached steady state within
0.5 h and the free concentration remained high for at least 3 h
compared to uncoated PDMS with HEK293T cells. For both com-
pounds, no differences were found between coated PDMS with and
without cells, indicating that the coatings remained intact during
cell culture and stable over longer periods of cell culture.
Overall, the study clearly showed the importance of deter-
mining the residual compound in the incubation ﬂuid at the end of
cellular dose response bioassays as part of dose response validation.
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